Objective: The aim of the present study was to investigate the differences in quality of life (QOL) following complete or partial thyroidectomy and with regard to thyroid hormone replacement (LT4) therapy.Study Design: Patients who underwent thyroidectomy were asked to complete the validated thyroid‐specific ThyPRO QOL questionnaire at least 6 months following surgery.Setting: Tertiary medical center.Methods: Thyroid specific QOL questionnaire analysis.Results: A total of 190 patients completed the ThyPRO questionnaire. Of them 89 patients had complete thyroidectomy and 101 patients had unilateral thyroid lobectomy. The total thyroidectomy group had significantly worse overall QOL self‐assessment score than the lobectomy patients (p < 0.0001). Patients receiving LT4 therapy regardless of the extent of surgery, reported worse QOL compared to patients not receiving LT4.Conclusions: Quality of life following thyroid surgery is significantly related to hypothyroidism and the requirement for LT4 therapy, rather to the extent of surgery. The best QOL was reported in patients treated with lobectomy who did not require LT4 therapy.

Objectives: Laryngeal squamous cell carcinoma (SCC) is a predominantly male illness. Although the rate of female patients increased, a knowledge gap exists in the medical literature regarding gender‐based differences.Design: Retrospective cohort study.Setting: Adult patients treated for laryngeal SCC in a tertiary medical centre between 2006 and 2020. Data were collected on demographics, clinical presentation, treatment modalities, disease recurrence and survival status.Participants: Two hundred ninety‐one patients with laryngeal SCC, 50 (17.2%) females and 241 (82.8%) males.Main Outcome Measures: Disease‐specific survival (DSS), overall survival (OS) and disease‐free survival (DFS), as well as differences in disease characteristics and treatment modalities.Results: Tumour subsites differed significantly between females and males (36% vs. 19.5% supraglottic, 62% vs. 80.5% glottic and 2% vs. 0% subglottic, respectively; p = 0.006). Females were diagnosed at younger ages (61.7 ± 10.58 vs. 65.87 ± 11.11 years, p = 0.016) and advanced‐stage disease (58% vs. 39.4%, p = 0.018). Females were treated with combined modalities at higher rates (36% vs. 54.8% for single modality, p = 0.031). DSS rates did not differ between genders (log‐rank p = 0.12). Despite being diagnosed at more advanced disease stages, females demonstrated prolonged median OS compared to males (130.17 vs. 106.17 months, log‐rank p = 0.017). No significant differences in DFS were observed (log‐rank p = 0.32). In a multivariate Cox proportional hazards model, male gender remained an independent negative OS predictor (HR = 2.08; CI, 1.10–3.96; p = 0.025), along with increasing age (HR = 1.06; CI, 1.04–1.09; p < 0.001) and advanced disease stage (HR = 1.7; CI, 1.08–2.67; p = 0.023).Conclusions: Our findings suggest the importance of considering gender‐specific factors in the management of laryngeal SCC.

Background: Robotic technology has proven safe and effective for thyroidectomy procedures. Few studies have addressed the quality-of-life outcomes of robotic thyroidectomy compared with conventional thyroidectomy. Materials and Methods: The database of a tertiary medical center was retrospectively reviewed for all patients with thyroid disease who had undergone robotic hemithyroidectomy in 2012–2020. All patients treated by transaxillary robotic surgery and a similar number of randomly selected patients treated by conventional cervical surgery completed a standardized self-administered thyroid disease–specific quality-of-life (QOL) questionnaire (ThyPRO). Clinical data were derived from the medical files. The results were compared using mean comparison tests and multivariate logistic regression models. Results: The cohort consisted of 131 patients: 63 after robotic thyroidectomy and 68 after conventional thyroidectomy. The mean age was 38.87 ± 14.11 and 58.85 ± 14.1 years, respectively (P < .0001). The robotic hemithyroidectomy group reported better QOL outcomes in physical and mental health parameters, including decreased anxiety, depression, lower sex life impairment, and cognitive impairment scores (P < .0001). Furthermore, after adjusting for age, gender, malignancy status, and surgical approach, we found that patients undergoing robotic hemithyroidectomy had a lower probability of experiencing depressive symptoms than the conventional hemithyroidectomy group (odds ratio = 0.31; 95% confidence interval, 0.11–0.88). Of interest, no significant difference in cosmetic outcomes was found. Conclusions: Patients who underwent robotic thyroidectomy report better postoperative QOL after surgery than patients operated by the conventional approach in terms of anxiety, depression, cognitive and sex-life scores.

Initial deleterious effects of the COVID-19 pandemic on urologic oncology surgeries are well described, but the possible influence of vaccination efforts and those of pandemic conditions on surgical volumes is unclear. Our aim was to examine the association between changing vaccination status and COVID-19 burden throughout the pandemic and the volume of urologic oncology surgeries in Israel. This multi-center cross-sectional study included data collected from five tertiary centers between January 2019 and December 2021. All 7327 urologic oncology surgeries were included. Epidemiological data were obtained from the Israeli Ministry of Health database. A rising trend in total urologic oncology surgery volumes was observed with ensuing COVID-19 wave peaks over time ($X^2$ = 13.184, df = 3, p = 0.004). Total monthly surgical volumes correlated with total monthly hospitalizations due to COVID-19 (R = −0.36, p = 0.015), as well as with the monthly average Oxford Stringency Index (R = −0.31, p = 0.035). The cumulative percent of vaccinations and of new COVID-19 cases per month did not correlate with total monthly urologic surgery volumes. Our study demonstrates the gradual acclimation of the Israeli healthcare system to the COVID-19 pandemic. However, hospitalizations due to COVID-19, as well as restriction stringency, correlate with lower volumes of urologic oncological surgeries, regardless of the population’s vaccination status.

Background: Programmed-cell death protein 1 (PD-1) inhibitors have become standard of care in the treatment of advanced or metastatic cutaneous squamous cell carcinoma (cSCC). However, insufficient data exists regarding treatment outcomes and safety among elderly patients, including patients aged >85. Patients and Methods: We retrospectively reviewed patients aged >85 (n = 52) and compared them with two control groups: 46 patients aged 71-84 and 32 patients 85 had worse ECOG scores and less inclined to undergo surgery, no significant differences were noted in the overall response rates (68.8% and 76.1% for 85, P = .744) or disease control rates (75% and 82.6% for 85, P = .627). After IPTW adjustment, progression-free survival (PFS) did not differ between groups (HR = 1.08, 95% CI 0.55-2.13, P = .82). Cancer specific survival (CSS) also did not differ between groups (HR = 1.05, 95% CI 0.22-4.87, P = .955). However, overall survival (OS) was shorter among patients >85 (HR = 2.64, 95% CI 1.43-4.86, P = .002). Toxicity profiles were similar, although toxicity-related deaths occurred more frequently in the >85 cohort. Conclusion: Cemiplimab showed comparable efficacy and tolerability across age groups, with no significant difference in PFS and CSS, but shorter OS among very elderly patients with cSCC, reflecting competing non-cancer mortality rather than reduced treatment efficacy.